Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS …

Objectives Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple
sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy …

Importance Uncertainty remains about how aggressively to treat early multiple sclerosis.
High-efficacy disease-modifying therapies (DMTs) are often reserved for individuals …

Objective: The objective of this paper is to investigate demographic and disease factors
associated with changes in employment role and status in multiple sclerosis (MS). Methods …

Background Age of onset of multiple sclerosis (MS) peaks in the 3rd and 4th decades and is
rarely less than 18. Robust longitudinal studies in paediatric-onset MS (POMS) are limited …

OBJECTIVE: The expression of clinically significant depression symptoms during and post
multiple sclerosis (MS) relapse was investigated. The point prevalence of possible …

Objective To examine the association between socioeconomic status (SES) and disability
outcomes and progression in multiple sclerosis (MS). Methods Health administrative and MS …

Objective: Alemtuzumab is potentially a highly effective treatment for relapsing multiple
sclerosis (MS) acting via complement-mediated lysis of circulating lymphocytes. Variability in …

Background A minority of patients with multiple sclerosis (MS) have primary progressive
disease (PPMS). Treatment options are currently limited, but as prospects for interventional …